0001209191-23-011665.txt : 20230222
0001209191-23-011665.hdr.sgml : 20230222
20230222163012
ACCESSION NUMBER: 0001209191-23-011665
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230217
FILED AS OF DATE: 20230222
DATE AS OF CHANGE: 20230222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 23653599
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-17
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, COO
Common Stock
2023-02-17
4
F
0
4498
292.85
D
71107
D
Common Stock
2023-02-21
4
S
0
21
291.01
D
71086
D
Common Stock
2023-02-21
4
S
0
545
292.77
D
70541
D
Common Stock
2023-02-21
4
S
0
1100
293.74
D
69441
D
Common Stock
2023-02-21
4
S
0
736
294.58
D
68705
D
Common Stock
140
I
401(k)
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $292.77 (range $292.25 to $293.07).
Open market sales reported on this line occurred at a weighted average price of $293.74 (range $293.30 to $294.19).
Open market sales reported on this line occurred at a weighted average price of $294.58 (range $294.36 to $294.96).
/s/ Christiana Stevenson, Attorney-in-Fact
2023-02-22